MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

Kodu・Aktsiate loetelu・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Avatud

SektorTervishoid

1.36 -4.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.3599999999999999

Max

1.3599999999999999

Põhinäitajad
By Trading Economics
Sissetulek	293K 540K
Müük	-3.7M 59M
Kasumimarginaal	0.919
Töötajad	181
EBITDA	-1.2M 6.2M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+280.54% upside

Turustatistika
By TradingEconomics
Turukapital	-161M 401M
Eelmine avamishind	5.59
Eelmine sulgemishind	1.36

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

2.345 / N/A Toetus ja vastupanu

Akebia Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. jaan 2026, 19:05 UTC

Suurimad hinnamuutused turgudel

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. jaan 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. jaan 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. jaan 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. jaan 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. jaan 2026, 23:10 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. jaan 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. jaan 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. jaan 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. jaan 2026, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. jaan 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. jaan 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. jaan 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. jaan 2026, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. jaan 2026, 19:03 UTC

Tulu

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. jaan 2026, 18:50 UTC

Tulu

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. jaan 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. jaan 2026, 17:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

13. jaan 2026, 17:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. jaan 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. jaan 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

13. jaan 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. jaan 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Akebia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

280.54% tõus

12 kuu keskmine prognoos

Keskmine 5.67 USD 280.54%

Kõrge 6 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Akebia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Akebia Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.345 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

Finantsandmed

Ettevõttest Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.